iBio, Inc. (IBIO) Earnings
IBIO has beaten EPS estimates in 2 of its last 10 reported quarters (average surprise -19.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.06 | $-0.07 | -16.7% | — | — |
| Nov 12, 2025 | $-0.07 | $-0.11 | -57.1% | $100000 | +200.0% |
| Sep 5, 2025 | $-0.39 | $-0.31 | +20.5% | $200000 | +100.0% |
| May 2, 2025 | $-0.39 | $-0.49 | -25.6% | — | — |
| Sep 25, 2024 | $-0.47 | $-0.91 | -93.6% | $175000 | — |
| Feb 9, 2024 | — | $-2.42 | — | — | — |
| Nov 14, 2023 | — | $-4.20 | — | $50000 | — |
| May 11, 2023 | $-3.42 | $-6.61 | -93.4% | $200000 | +0.0% |
| Feb 14, 2023 | $-146.90 | $-21.60 | +85.3% | — | — |
| Nov 14, 2022 | $-1.85 | $-2.05 | -10.8% | $56000 | -90.7% |
| May 12, 2022 | $-1.25 | $-30.00 | -2300.0% | $2M | +871.5% |
| Feb 14, 2022 | $-1.00 | $-25.00 | -2400.0% | $168000 | -32.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2022 · September 27, 2022
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Tom discussed the acquisition of RubrYc, which enables acceleration of bringing immunotherapies to clinic faster. RubrYc's platform includes AI-driven drug discovery, two licensed candidates (IBIO-101 and Target 6), and four new pipeline assets. - Martin detailed RubrYc’s AI-powered discovery platform with modules for identifying epitopes, using antibody library, and optimizing leads. Provided pipeline updates: IBIO-101 pre-IND submitted, expected IND filing in first half of 2024; IBIO-202 COVID-19 vaccine candidate didn't provide protective effect in hamster studies. - Rob gave financial highlights, mentioned reverse stock split effective October 7, 2022.
Guidance
- Evaluating options to extend cash runway past September 30, 2023, including asset sales, partnerships, cost reductions. - Reviewing non-dilutive and dilutive ways to raise additional capital. - No guarantee of success in extending cash runway but confident in evaluating options.
Segment performance
For the fiscal year ended June 30, 2022, revenues were approximately $2.4 million, essentially flat versus prior year. R&D expenses increased by approximately $7.7 million and G&A expenses increased by $12.1 million over the comparable period in fiscal 2021. The consolidated net loss for the fiscal year was approximately $50.3 million. Cash, cash equivalents and investments in debt securities were approximately $39.5 million as of June 30, 2022.
Risks & headwinds
- Substantial doubt about the company's ability to continue as a going concern. - No assurance of success in implementing options to extend cash runway.
Analyst Q&A
Q: From a timing perspective, what led to closing on assets from RubrYc now versus original agreement?
A: Tom said relationship with RubrYc was running for a year, they got hands-on experience with the platform, and saw progress with the platform and other molecules. Martin added they had proof-of-concept of the technology platform.
Q: What remains to be done ahead of submitting IND for IBIO-101 and timeline for other assets?
A: Tom said they're evaluating resource allocation, going as fast as possible with IBIO-101 but also evaluating opportunities. For other assets like Target 6, PD-1 agonist, they think they could be in in vivo proof-of-concept soon but didn't give exact range.
Q: Concerns about transparency, compensation, and financials?
A: Tom responded iBio has been transparent with frequent updates and conference calls. Addressed compensation and business decisions regarding IBIO-202, stating they made tough decisions based on biology and market conditions.